Brought to you by 
Breath licenses Pari's drug/device combo product
13 Sep 2017
Executive Summary
As part of its spin off from Pari Pharma GMBH, Breath Therapeutics Holding BV received a Phase III-ready program for bronchiolitis obliterans syndrome (BOS), a deadly respiratory disease which mostly affects lung transplant patients.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Breath licenses Pari's drug/device combo product
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice